公开(公告)号：US10119976B2

公开(公告)日：2018-11-06

申请号：US14893989

申请日：2014-05-27

Applicant: Biogen MA Inc.

Inventor： Gary Lewis Bloomgren ,  Carmen Bozic ,  Sophia Lee ,  Amy Pace ,  Tatiana Plavina ,  Meena Subramanyam

IPC: C12Q1/68 ,  C07H21/02 ,  C07H21/04 ,  A61K39/00 ,  C12P19/34 ,  G01N33/68 ,  G01N33/569 ,  C12N7/00 ,  C07K16/28 ,  C12Q1/70

Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).

公开(公告)号：US20160116483A1

公开(公告)日：2016-04-28

申请号：US14893989

申请日：2014-05-27

Applicant: BIOGEN MA INC.

Inventor： Gary Lewis Bloomgren ,  Carmen Bozic ,  Sophia Lee ,  Amy Pace ,  Tatiana Plavina ,  Meena Subramanyam

IPC: G01N33/68 ,  C07K16/28

CPC classification number: G01N33/6854 ,  C07K16/2842 ,  C07K2317/24 ,  C12N7/00 ,  C12N2710/22011 ,  C12Q1/70 ,  G01N33/56983 ,  G01N2333/025 ,  G01N2469/20 ,  G01N2800/24 ,  G01N2800/28 ,  G01N2800/50

Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).

Abstract translation: 本发明涉及评估患者进展性多灶性脑白质病（PML）风险的方法。

公开(公告)号：US12105090B2

公开(公告)日：2024-10-01

申请号：US16211154

申请日：2018-12-05

Applicant: BIOGEN MA INC.

Inventor： Gary Lewis Bloomgren ,  Carmen Bozic ,  Sophia Lee ,  Meena Subramanyam ,  Tatiana Plavina

IPC: A61K39/395 ,  A61K39/00 ,  G01N33/53 ,  G01N33/569

CPC classification number: G01N33/56983 ,  C12N2710/22011 ,  G01N2333/025 ,  G01N2469/20 ,  G01N2800/28 ,  G01N2800/2814 ,  G01N2800/50 ,  G01N2800/52

Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).

公开(公告)号：US12031990B2

公开(公告)日：2024-07-09

申请号：US17700250

申请日：2022-03-21

Applicant: BIOGEN MA INC.

Inventor： Gary Lewis Bloomgren ,  Carmen Bozic ,  Sophia Lee ,  Amy Pace ,  Tatiana Plavina ,  Meena Subramanyam

IPC: G01N33/569 ,  C07K16/08 ,  C07K16/28 ,  C12N7/00 ,  G01N33/53 ,  G01N33/68 ,  C12Q1/70

CPC classification number: G01N33/6854 ,  C07K16/2842 ,  C12N7/00 ,  G01N33/56983 ,  C07K2317/24 ,  C12N2710/22011 ,  C12Q1/70 ,  G01N2333/025 ,  G01N2469/20 ,  G01N2800/24 ,  G01N2800/28 ,  G01N2800/50

Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).

公开(公告)号：US11686734B2

公开(公告)日：2023-06-27

申请号：US16923043

申请日：2020-07-07

Applicant: Biogen MA Inc.

Inventor： Meena Subramanyam ,  Lakshimi Amaravadi ,  Eric Wakshull ,  Frances Lynn ,  Michael Panzara ,  Robin McDaid Barbour ,  Julie Elizabeth Taylor

IPC: G01N33/68 ,  C07K16/28

CPC classification number: G01N33/6854 ,  C07K16/2839 ,  G01N33/686 ,  G01N2333/70546 ,  G01N2800/065 ,  G01N2800/102 ,  G01N2800/285 ,  G01N2800/52

Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).

公开(公告)号：US11280794B2

公开(公告)日：2022-03-22

申请号：US16896074

申请日：2020-06-08

Applicant: BIOGEN MA INC.

Inventor： Gary Lewis Bloomgren ,  Carmen Bozic ,  Sophia Lee ,  Amy Pace ,  Tatiana Plavina ,  Meena Subramanyam

IPC: A61K39/00 ,  A61K9/00 ,  C07K16/28 ,  C12N7/00 ,  G01N33/68 ,  G01N33/569 ,  C12Q1/70

Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).

公开(公告)号：US20220011310A1

公开(公告)日：2022-01-13

申请号：US17393335

申请日：2021-08-03

Applicant: Biogen MA Inc.

Inventor： Gary Lewis Bloomgren ,  Carmen Bozic ,  Sophia Lee ,  Meena Subramanyam ,  Tatiana Plavina

IPC: G01N33/569

Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).

公开(公告)号：US10444234B2

公开(公告)日：2019-10-15

申请号：US15063777

申请日：2016-03-08

Applicant: Biogen MA Inc.

Inventor： Leonid Gorelik ,  Kenneth J. Simon ,  Meena Subramanyam ,  Mia Marie Rushe

IPC: C12Q1/70 ,  G01N33/569

Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.

公开(公告)号：US09709575B2

公开(公告)日：2017-07-18

申请号：US14330619

申请日：2014-07-14

Applicant: Biogen MA Inc.

Inventor： Meena Subramanyam ,  Lakshmi Amaravadi ,  Eric Wakshull ,  Frances Lynn ,  Michael Panzara ,  Robin McDaid Barbour ,  Julie Elizabeth Taylor

IPC: C07K16/28 ,  G01N33/68

CPC classification number: G01N33/6854 ,  C07K16/2839 ,  G01N33/686 ,  G01N2333/70546 ,  G01N2800/065 ,  G01N2800/102 ,  G01N2800/285 ,  G01N2800/52

Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titer of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titer of untreated patients increased by the double of the standard deviation of this control antibody titer.